Fig. 7: Combination of PIN1- and CDK4-inhibitors achieves synergistic anti-tumor immunity and efficacy against RB-proficient or -deficient TNBC in immune-competent mouse models.
From: Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
Growth curve (a) and survival curve (b) generated from FVB mice bearing K14cre; Brca1wt/f; p53wt/f_BT3 tumors treated with vehicle (median survival of 18 days), Sulfopin (median survival of 21 days), Palbociclib (median survival of 21 days) or their combination (median survival of 34.5 days), n = 10 mice per group. Growth curve (c) and survival curve (d) generated from FVB mice bearing K14cre; Brca1wt/f; p53wt/f_BT3 tumors treated with vehicle (median survival of 19 days), Sulfopin (median survival of 25 days), Abemaciclib median survival of 25 days) or their combination (median survival of 55 days), n = 10 mice per group. Data are mean ± SEM and analyzed by two-sided unpaired student’s t-test (a, c) or log-rank test (b, d). p values are shown (a–d). e Concatenated UMAP plots displaying 24,000 CD45+ cells derived from K14cre; p53wt/f; Brca1wt/f mouse tumors treated with Sulfopin, Abemaciclib or their combination for two weeks and colored by the main cell populations based on manual annotation of PhenoGraph clustering. f Individual UMAPs for CD45+ cells from different treatments. g–l The violin plots generated by CyTOF data showing percentages of indicated cells from different treatments. n = 7 per group. Data in graphs are analyzed by unpaired two-sided t-test. Vehicle vs. Combination, p values are shown. Source data are provided as a Source Data file.
